30-day average of 6 articles ยท scale โ100 to +100
Across 6 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Edwards Lifesciences news is Bullish (+64)
on a scale from โ100 to +100.
That is up 15 points from the previous 30 days (+49).
๐ VP Donald Bobo, Jr. sold 48,900 shares for $5.04 million under a pre-arranged Rule 10b5-1 trading plan on November 9th.
๐ฐ The company reported Q3 EPS of $0.80, beating the consensus estimate of $0.74 by $0.06.
๐ Revenue reached $1.72 billion, surpassing the $1.68 billion consensus and growing 10.5% year-over-year.
๐ฆ Institutional ownership stands at 79.46%, with Intech Investment Management increasing its stake by 123.9% in Q3.
๐ฏ Analysts maintain a 'Moderate Buy' consensus with an average price target of $108.88, up from recent lows.
๐ The stock trades at a P/E ratio of 59.16 and has a market capitalization of $60.29 billion.
๐ Bullish signals
๐ฐEdwards Lifesciences beat Q3 earnings estimates with $0.80 EPS versus the consensus of $0.74.
๐Revenue grew 10.5% year-over-year to $1.72 billion, exceeding analyst expectations of $1.68 billion.
๐ฏGoldman Sachs raised its price target to $102.00 and reaffirmed a 'buy' rating on the stock.
๐ฆIntech Investment Management increased its stake by 123.9% in Q3, now holding shares valued at $16.6 million.
๐ฏTruist Financial set a price objective of $113.00 with a 'buy' rating following the earnings beat.
๐ฏPiper Sandler raised its price target to $115.00 and maintained an 'overweight' rating on the company.
๐ Risk factors
๐VP Donald Bobo, Jr. reduced his personal shareholding by 68.2% following a $5.04 million sale.
๐The stock trades at a high P/E ratio of 59.16, which may limit upside potential if growth slows.
Article
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents a significant decrease in his position but was executed via a standard compliance plan.
The company reported strong quarterly financial results on November 4th, beating analyst expectations for both earnings per share and revenue. Edwards Lifesciences posted $0.80 EPS compared to the consensus of $0.74, while revenue reached $1.72 billion against an estimate of $1.68 billion. Year-over-year revenue growth stood at 10.5%, driven by its structural heart disease therapies and critical care technologies.
Market sentiment remains robust with a consensus price target of $108.88, supported by recent upgrades from major analysts including Goldman Sachs, Jefferies, and Truist Financial. Institutional ownership is high at 79.46%, with several funds like Intech Investment Management increasing their stakes in the third quarter. The stock trades at a P/E ratio of 59.16 with a market capitalization of $60.29 billion.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents a significant decrease in his position but was executed via a standard compliance plan.
The company reported strong quarterly financial results on November 4th, beating analyst expectations for both earnings per share and revenue. Edwards Lifesciences posted $0.80 EPS compared to the consensus of $0.74, while revenue reached $1.72 billion against an estimate of $1.68 billion. Year-over-year revenue growth stood at 10.5%, driven by its structural heart disease therapies and critical care technologies.
Market sentiment remains robust with a consensus price target of $108.88, supported by recent upgrades from major analysts including Goldman Sachs, Jefferies, and Truist Financial. Institutional ownership is high at 79.46%, with several funds like Intech Investment Management increasing their stakes in the third quarter. The stock trades at a P/E ratio of 59.16 with a market capitalization of $60.29 billion.
๐ VP Donald Bobo sold 48,900 shares for $5.04 million via Rule 10b5-1 plan.
๐ฐ Q3 EPS hit $0.80, beating the $0.74 consensus estimate by $0.06.
๐ Revenue reached $1.72 billion, up 10.5% year-over-year and above consensus.
๐ฆ Institutional ownership is 79.46%, with Intech Investment Management stake rising 123.9%.
๐ฏ Analysts hold 'Moderate Buy' rating with average price target of $108.88.
๐ VP Donald Bobo, Jr. sold 48,900 shares for $5.04 million under a pre-arranged Rule 10b5-1 trading plan on November 9th.
๐ฐ The company reported Q3 EPS of $0.80, beating the consensus estimate of $0.74 by $0.06.
๐ Revenue reached $1.72 billion, surpassing the $1.68 billion consensus and growing 10.5% year-over-year.
๐ฆ Institutional ownership stands at 79.46%, with Intech Investment Management increasing its stake by 123.9% in Q3.
๐ฏ Analysts maintain a 'Moderate Buy' consensus with an average price target of $108.88, up from recent lows.
๐ The stock trades at a P/E ratio of 59.16 and has a market capitalization of $60.29 billion.
Bullish Signals
EPS beat estimates at $0.80 vs $0.74 consensus.
Risk Factors
VP Bobo sold shares worth $5.04M, reducing stake by 68.2%.
High P/E of 59.16 limits upside if growth slows.
Bullish Signals
Edwards Lifesciences beat Q3 earnings estimates with $0.80 EPS versus the consensus of $0.74.
Revenue grew 10.5% year-over-year to $1.72 billion, exceeding analyst expectations of $1.68 billion.
Goldman Sachs raised its price target to $102.00 and reaffirmed a 'buy' rating on the stock.
Intech Investment Management increased its stake by 123.9% in Q3, now holding shares valued at $16.6 million.
Truist Financial set a price objective of $113.00 with a 'buy' rating following the earnings beat.
Piper Sandler raised its price target to $115.00 and maintained an 'overweight' rating on the company.
Risk Factors
VP Donald Bobo, Jr. reduced his personal shareholding by 68.2% following a $5.04 million sale.
The stock trades at a high P/E ratio of 59.16, which may limit upside potential if growth slows.
Edwards Lifesciences Corporation reported its financial results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company generated sales of USD 1,715.5 million, representing an increase from USD 1,553.1 million in the same period last year. Net income rose to USD 307.5 million compared to USD 291.1 million a year ago, while basic and diluted earnings per share from continuing operations both reached USD 0.53, up from USD 0.50 in the prior-year quarter.
Over the nine-month period ending September 30, 2026, Edwards Lifesciences achieved total sales of USD 5,105.1 million, a significant increase from USD 4,498 million reported for the same timeframe in the previous year. However, net income for the nine months decreased to USD 930.1 million compared to USD 982.3 million a year ago. Consequently, basic earnings per share from continuing operations fell to USD 1.61 from USD 1.70, and diluted earnings per share dropped to USD 1.61 from USD 1.67 during the nine-month period.
๐ Q3 sales rose to $1,715.5M, up from $1,553.1M prior year.
๐ฐ Q3 net income increased to $307.5M versus $291.1M last year.
๐ Q3 EPS grew to $0.53 from $0.50 in the prior quarter.
๐ Nine-month sales reached $5,105.1M, exceeding $4,498M a year ago.
โ ๏ธ Nine-month net income fell to $930.1M from $982.3M last year.
๐ Edwards Lifesciences reported third-quarter sales of USD 1,715.5 million, an increase from USD 1,553.1 million in the prior-year quarter.
๐ฐ Net income for the third quarter rose to USD 307.5 million compared to USD 291.1 million a year ago.
๐ Basic and diluted earnings per share from continuing operations were USD 0.53, up from USD 0.50 in the previous year's quarter.
๐ Nine-month sales reached USD 5,105.1 million, surpassing the prior-year total of USD 4,498 million.
โ ๏ธ Net income for the nine months declined to USD 930.1 million compared to USD 982.3 million a year ago.
๐ Basic earnings per share from continuing operations for the nine-month period decreased to USD 1.61 from USD 1.70.
Bullish Signals
Revenue grew 14% to USD 1,715.5 million.
Net income rose to USD 307.5 million.
EPS improved to USD 0.53.
Risk Factors
Net income declined to USD 930.1M vs USD 982.3M prior-year.
EPS decreased to USD 1.61 from USD 1.70 last year.
Bullish Signals
Edwards Lifesciences achieved third-quarter sales growth, reporting USD 1,715.5 million in revenue compared to USD 1,553.1 million a year ago.
The company posted an increase in net income for the third quarter, reaching USD 307.5 million versus USD 291.1 million in the prior-year period.
Earnings per share from continuing operations improved in the third quarter to USD 0.53, up from USD 0.50 a year ago.
Risk Factors
Net income for the nine months ended September 30, 2026, declined to USD 930.1 million compared to USD 982.3 million in the prior-year period.
Basic earnings per share from continuing operations decreased to USD 1.61 for the nine-month period, down from USD 1.70 a year ago.
Edwards Lifesciences (NYSE:EW) presented new clinical data demonstrating significant patient benefits from its PASCAL and TAVR programs. The CLASP IITR trial for the PASCAL transcatheter edge-to-edge repair system met its six-month primary endpoint, showing treated patients were nearly twice as likely to experience a composite benefit compared to those receiving medical therapy alone.
The primary driver of this improvement was enhanced quality of life, measured by KCCQ scores, with 57% of device-treated patients achieving moderate-to-large improvements versus 25% in the control group. At one year, 80% of PASCAL patients maintained moderate or less tricuspid regurgitation compared to only 30% of controls, indicating sustained efficacy in managing severe tricuspid regurgitation.
Additionally, Edwards highlighted the PROGRESS trial evaluating TAVR in patients with moderate aortic stenosis and high-risk features. The study found that TAVR reduced the two-year risk of death or heart-failure events by 33%, primarily driven by a 52% reduction in heart-failure hospitalizations. While these findings suggest potential for label expansion, Edwards noted that moderate aortic stenosis is not yet an approved indication and no timeline was provided.
The data reinforces Edwards' position as a leader in structural heart disease therapies, addressing underdiagnosed conditions like tricuspid regurgitation and redefining the management of moderate aortic stenosis. Executives emphasized that these trials were designed in collaboration with the FDA to assess patient populations previously considered for surveillance rather than intervention.
๐ PASCAL trial met primary endpoint; treated patients nearly twice as likely to benefit vs medical therapy.
๐ 57% of PASCAL patients achieved moderate-to-large quality-of-life improvements versus 25% in control group.
๐ฅ One-year follow-up shows 80% of PASCAL patients achieved moderate or less tricuspid regurgitation.
โค๏ธ PROGRESS trial reduced two-year risk of death or heart-failure events by 33% in high-risk patients.
๐ฌ ACTIVATE analysis reveals 80% of moderate aortic stenosis patients have at least one high-risk feature.
๐ Edwards Lifesciences' PASCAL system met its six-month primary endpoint in the CLASP IITR trial, with treated patients nearly twice as likely to benefit compared to medical therapy alone.
๐ Quality of life improvements were the main driver for the PASCAL trial, with 57% of device-treated patients achieving moderate-to-large KCCQ score improvements versus 25% in the control group.
๐ฅ At one year follow-up, 80% of PASCAL patients achieved moderate or less tricuspid regurgitation compared to just 30% of patients receiving optimal medical therapy alone.
โค๏ธ The PROGRESS trial demonstrated that TAVR reduced the two-year risk of death or heart-failure events by 33% in high-risk patients with moderate aortic stenosis.
๐ฅ Heart-failure hospitalizations were reduced by 52% among patients treated with TAVR in the PROGRESS study, significantly improving patient outcomes over clinical surveillance.
๐ฌ Edwards Lifesciences highlighted that tricuspid regurgitation remains underdiagnosed, and the PASCAL data supports earlier intervention for symptomatic patients.
๐ The ACTIVATE analysis revealed that 80% of moderate aortic stenosis patients had at least one high-risk feature, suggesting many may benefit from TAVR despite current approval limitations.
๐ค Both the CLASP IITR and PROGRESS trials were designed in collaboration with the FDA to evaluate specific patient populations for potential future label expansions.
Bullish Signals
PASCAL system met endpoint; treated patients twice as likely to benefit.
Bullish Signals
Edwards Lifesciences' PASCAL system met its six-month primary endpoint, with treated patients nearly twice as likely to experience a composite benefit compared to medical therapy alone.
The CLASP IITR trial showed that 57% of device-treated patients achieved moderate-to-large improvements in quality of life scores, significantly outperforming the 25% improvement rate in the control group.
At one year, 80% of PASCAL patients maintained moderate or less tricuspid regurgitation compared to only 30% of controls, demonstrating sustained efficacy in valve repair.
The PROGRESS trial found that TAVR reduced the two-year risk of death or heart-failure events by 33% in high-risk patients with moderate aortic stenosis.
Edwards Lifesciences' TAVR treatment resulted in a 52% reduction in heart-failure hospitalizations, primarily driving the overall benefit observed in the PROGRESS study.
The ACTIVATE analysis indicated that 80% of moderate aortic stenosis patients had at-risk features, highlighting a large potential patient population for Edwards' TAVR technology.
Wall Street analysts project Edwards Lifesciences (EW) to report quarterly earnings of $0.73 per share, marking a 9% year-over-year increase. Revenue is estimated at $1.68 billion, representing an 8% rise from the prior-year quarter. Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.1%, reflecting analysts' collective reassessment of their initial projections.
Analyst forecasts for specific product groups indicate strong growth in Edwards' structural heart therapies. Net sales for Transcatheter Mitral and Tricuspid Therapies are expected to reach $195.98 million, a 35% increase year-over-year. Surgical Structural Heart revenue is projected at $267.05 million, up 3.5%, while Transcatheter Aortic Valve Replacement sales are estimated at $1.21 billion, reflecting a 5.1% gain.
In the broader market context, Edwards Lifesciences shares have outperformed significantly over the past month, returning +10.9% compared to the Zacks S&P 500 composite's +0.7% change. Despite this recent momentum, the stock currently carries a Zacks Rank #3 (Hold), suggesting that future performance may align more closely with overall market trends in the near future.
๐ Analysts project quarterly earnings of $0.73, up 9% year-over-year.
๐ฐ Revenue estimated at $1.68 billion, an 8% increase.
โค๏ธ Transcatheter mitral/tricuspid therapies sales forecast at $195.98 million.
๐ช Surgical structural heart revenue expected to hit $267.05 million.
๐ Shares gained +10.9% over the past month versus S&P 500.
๐ Analysts project Edwards Lifesciences quarterly earnings of $0.73 per share, representing a 9% year-over-year increase.
๐ฐ Revenue is estimated to reach $1.68 billion, an 8% rise from the same quarter last year.
๐ The consensus EPS estimate has been adjusted upward by 0.1% over the past 30 days.
โค๏ธ Net sales for Transcatheter Mitral and Tricuspid Therapies are forecast at $195.98 million, up 35% year-over-year.
๐ช Surgical Structural Heart revenue is expected to hit $267.05 million, a 3.5% increase from the prior quarter.
๐ฉบ Transcatheter Aortic Valve Replacement sales are projected at $1.21 billion, reflecting a 5.1% year-over-year change.
๐ Edwards Lifesciences shares returned +10.9% over the past month versus the S&P 500 composite's +0.7% gain.
โ๏ธ The stock currently holds a Zacks Rank #3 (Hold), indicating potential alignment with overall market performance.
Bullish Signals
EPS projected at $0.73, up 9% YoY.
Revenue forecast hits $1.68B, an 8% rise.
Consensus EPS revised up 0.1% recently.
TMT therapies sales surge 35% to $196M.
Bullish Signals
Analysts project quarterly earnings of $0.73 per share, representing a significant 9% year-over-year increase.
Revenue is forecast to reach $1.68 billion, marking an 8% growth from the prior-year quarter.
The consensus EPS estimate has been revised upward by 0.1% over the past month, signaling improved analyst confidence.
Transcatheter Mitral and Tricuspid Therapies are expected to generate $195.98 million in net sales, a robust 35% year-over-year surge.
Edwards Lifesciences shares have outperformed the broader market with a +10.9% return over the past month.
Edwards Lifesciences (NYSE: EW) announced that the U.S. Food and Drug Administration has approved its PASCAL Precision device for a new indication in severe symptomatic tricuspid regurgitation. This approval covers patients with leakage who have not responded to optimal medical therapy and are at intermediate or greater surgical risk, marking a significant expansion of Edwards' structural heart portfolio.
The company plans to present one-year pivotal results from the CLASP II TR study at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego. While the FDA approval was granted, the release did not include specific outcome figures, analyzed patient counts, or a separate launch date for the new tricuspid therapy in the United States.
Edwards shares rose 0.84% to $89.00 following the news, reflecting investor interest in the broadened reach of its transcatheter repair capabilities. The company now offers both mitral and tricuspid transcatheter repair and replacement therapies, positioning itself alongside competitors like Abbott Laboratories' TriClip system, though no head-to-head comparison data was provided.
๐ฅ FDA approved PASCAL Precision for severe tricuspid regurgitation in high-risk patients.
๐ Stock rose 0.84% to $89.00 following the regulatory approval announcement.
๐ฌ CLASP II TR study will present one-year findings at late October TCT meeting.
๐ผ Edwards now offers complete transcatheter repair and replacement therapies for mitral and tricuspid valves.
๐ฅ Edwards Lifesciences received FDA approval for the PASCAL Precision device to treat severe symptomatic tricuspid regurgitation in patients failing medical therapy.
๐ The stock price increased by 0.84% to $89.00 on the NYSE immediately following the regulatory announcement.
๐ฌ Edwards plans to present one-year pivotal findings from the CLASP II TR study at the TCT cardiology meeting scheduled for late October.
๐ฅ The new indication targets patients with severe leakage who are suitable for transcatheter edge-to-edge repair and face intermediate or greater surgical risk.
๐ผ Edwards now offers a complete portfolio of transcatheter repair and replacement therapies for both mitral and tricuspid valves in the U.S.
๐ The CLASP II TR study involves an estimated enrollment of 1,270 patients across randomized and registry cohorts to assess long-term outcomes.
โ๏ธ The approval places Edwards' PASCAL device alongside Abbott Laboratories' TriClip system as a nonsurgical treatment option for tricuspid regurgitation.
Bullish Signals
FDA approved PASCAL for severe tricuspid regurgitation.
Stock rose 0.84% to $89.00 on news.
Bullish Signals
Edwards Lifesciences secured FDA approval for a new indication of its PASCAL Precision device, expanding its structural heart portfolio to include severe symptomatic tricuspid regurgitation.
The company's stock price rose 0.84% to $89.00 on the NYSE following the positive regulatory news regarding the tricuspid valve therapy.
Edwards Lifesciences Corp (NYSE: EW) shares rallied 4.05% in morning trading following the release of third-quarter earnings that beat analyst estimates by $0.09 per share and $17.21 million in revenue. The company reported EPS of $1.07 on revenues of $615.5 million, exceeding expectations for both metrics.
Management provided solid guidance for the upcoming quarter, projecting EPS between $1.11 and $1.21 and revenue ranging from $620 million to $660 million, which slightly trails consensus estimates but reflects a cautious yet stable outlook. The stock has gained 20.64% year-to-date as investors remain optimistic about future growth opportunities.
Institutional sentiment remains strong with hedge funds increasing their exposure; 46 of the tracked elite funds reported stakes worth $2.16 billion by the end of June, up from $1.72 billion in March. Notably, AQR Capital Management increased its position to 2.4 million shares, signaling continued confidence in the company's trajectory.
๐ EW shares rose 4.05% after Q3 EPS and revenue beat estimates.
๐ฐ EPS exceeded expectations by $0.09 while revenue surpassed forecasts by $17.21M.
๐ฎ Next quarter EPS guidance is $1.11-$1.21, though revenue outlook is below consensus.
๐ Stock gained 20.64% year-to-date as investors remain optimistic about growth.
๐ฆ Hedge fund stakes rose to $2.16B with AQR increasing position to 2.4M shares.
๐ Edwards Lifesciences Corp (EW) shares rose 4.05% after reporting Q3 EPS of $1.07 and revenue of $615.5 million, both beating analyst estimates.
๐ฐ The company delivered a solid beat with earnings per share exceeding expectations by $0.09 and revenue surpassing forecasts by $17.21 million.
๐ฎ Management issued guidance for the next quarter expecting EPS between $1.11 and $1.21, though revenue guidance of $620M-$660M is slightly below consensus estimates.
๐ The stock has appreciated 20.64% year-to-date as investors maintain optimism regarding the company's future growth prospects.
๐ฆ Hedge fund sentiment is bullish with 46 elite funds holding stakes totaling $2.16 billion, an increase from $1.72 billion in March.
๐ AQR Capital Management specifically increased its position to 2.4 million shares by the end of the second quarter.
Bullish Signals
EPS beat estimates by $0.09 at $1.07.
Revenue exceeded expectations by $17.21 million.
Shares rallied 4.05% on strong earnings.
Forward guidance expects EPS of $1.11-$1.21.
Stock gained 20.64% year-to-date.
Risk Factors
Q4 revenue guidance of $620M-$660M trails analyst consensus of $630.68M.
Bullish Signals
Edwards Lifesciences Corp reported third-quarter earnings of $1.07 per share, beating analyst estimates by $0.09 per share.
The company's Q3 revenue reached $615.5 million, surpassing expectations by $17.21 million.
Shares rallied 4.05% in morning trading following the positive earnings surprise and solid financial performance.
Management provided forward guidance expecting quarterly EPS between $1.11 and $1.21 for the upcoming quarter.
The stock has gained 20.64% year-to-date, reflecting strong investor confidence in the company's growth trajectory.
Hedge fund ownership increased significantly with 46 elite funds holding stakes worth $2.16 billion as of June.
Risk Factors
Management's revenue guidance for the next quarter ($620M-$660M) is slightly below analyst consensus estimates of $630.68 million.
Edwards Lifesciences stock rose 1.26 percent to close at USD 89.45 on September 22, 2026, trading near its yearly high of USD 96.29. The company reported quarterly earnings per share (EPS) of USD 0.78, beating the consensus estimate of USD 0.74 by USD 0.04. This positive performance contributed to a market capitalization of USD 50.80 billion as of September 21, 2026.
The stock traded within a 52-week range between USD 72.30 and USD 96.29, with daily volume reaching 866,356 shares. Analyst consensus price targets from MarketBeat stand at USD 100.27, suggesting potential upside of approximately 11 percent from the current quote. The target range spans from USD 85.00 to USD 110.00.
Financial metrics indicate Edwards Lifesciences is trading at a price-to-earnings ratio of 50.70, which is above the cited market average of about 39.07. Year-over-year quarterly revenue growth was reported at 13.6 percent, while expected earnings growth for the coming year is projected at 13.00 percent, rising from USD 3.00 to USD 3.39 per share.
๐ EW stock rose 1.26% to close at USD 89.45 on Sept 22, 2026.
๐ฐ Quarterly EPS of USD 0.78 beat the consensus estimate of USD 0.74.
๐ Year-over-year revenue growth reached 13.6% in the latest period cited.
๐ฏ MarketBeat price target of USD 100.27 implies potential upside from current levels.
๐ P/E ratio of 50.70 is above the market average of 39.07.
๐ Edwards Lifesciences stock gained 1.26 percent to close at USD 89.45 on September 22, 2026.
๐ฐ The company reported quarterly EPS of USD 0.78, beating the consensus estimate of USD 0.74.
๐ Year-over-year quarterly revenue growth reached 13.6 percent in the latest period cited.
๐ฏ MarketBeat lists a consensus price target of USD 100.27, implying potential upside from current levels.
๐ The stock trades at a P/E ratio of 50.70, which is above the market average of 39.07.
๐ Expected earnings growth for the coming year is projected at 13.00 percent.
Bullish Signals
Stock rose 1.26% to $89.45, near yearly high of $96.29.
Beat EPS estimates with actuals of $0.78 vs consensus $0.74.
Achieved year-over-year quarterly revenue growth of 13.6%.
Risk Factors
P/E ratio of 50.70 exceeds market average of 39.07.
Bullish Signals
Edwards Lifesciences stock gained 1.26 percent to reach USD 89.45, trading near its yearly high of USD 96.29.
The company beat quarterly EPS estimates with actual results of USD 0.78 versus a consensus of USD 0.74.
Edwards Lifesciences achieved year-over-year quarterly revenue growth of 13.6 percent.
Risk Factors
The stock trades at a price-to-earnings ratio of 50.70, which is significantly above the cited market average of about 39.07.
Edwards Lifesciences (NYSE: EW) closed at $88.22 on September 18, 2026, showing a negligible 0.01% decline from the previous session. The stock traded within a range of $87.96 to $88.65 with a volume of 4.25 million shares, maintaining a market capitalization of approximately $50.80 billion. At this price point, the shares remained 8.3% below their 52-week high but were still trading 21.1% above their 52-week low.
The company's recent performance was supported by its July quarter results, where it reported earnings per share (EPS) of $0.78 on revenue of $1.74 billion. This earnings beat helped stabilize the stock price near the $88 level following the report. MarketBeat noted that these figures provided a solid foundation for investor sentiment heading into the current trading session.
Looking ahead, Edwards Lifesciences has issued guidance for the third quarter of 2026 with EPS expected between $0.710 and $0.770 per share. For the full fiscal year 2026, the company projects EPS to range from $2.950 to $3.050. These forward-looking metrics represent the latest official outlook available for investors as they assess the stock's trajectory before the bell.
๐ Stock closed at $88.22 with negligible 0.01% decline.
๐ฐ Q2 EPS hit $0.78 on $1.74 billion revenue.
๐ Q3 guidance set between $0.710 and $0.770 per share.
๐ฏ FY26 EPS outlook ranges from $2.950 to $3.050.
๐ Volume reached 4.25 million shares, trading 8.3% below high.
๐ Edwards Lifesciences closed at $88.22 on September 18, 2026, with a negligible 0.01% decline from the prior session.
๐ฐ The company reported EPS of $0.78 and revenue of $1.74 billion for the July quarter, supporting its stock price near $88.
๐ MarketBeat confirmed Q3 2026 guidance of $0.710 to $0.770 per share as the latest dated outlook for investors.
๐ฏ Full fiscal year 2026 EPS guidance stands between $2.950 and $3.050 per share according to recent reports.
๐ The stock traded with a volume of 4.25 million shares, remaining 8.3% below its 52-week high.
Edwards Lifesciences Corporation reported strong financial results for the quarter ended July 23, 2026, with shares closing at $88.22 on September 18, 2026. The company beat analyst expectations significantly, posting earnings per share of $0.78 compared to a consensus of $0.74 and generating revenue of $1.74 billion against an expected $1.70 billion.
Key performance metrics highlighted the strength of the business, with quarterly revenue rising 13.6% year over year and net margins reaching 15.43%. These figures provided a clear earnings anchor for the stock, demonstrating that growth was not only stronger than anticipated but also accompanied by healthy profitability levels.
Looking ahead, Edwards Lifesciences issued guidance for the third quarter of 2026 with EPS expected between $0.71 and $0.77, while full-year 2026 EPS guidance ranges from $2.95 to $3.05 per share. Analysts maintain a bullish outlook with an average price target of $100.27, suggesting potential upside for investors despite the stock trading below its 52-week high.
The market reaction was positive with trading volume reaching 4.25 million shares, well above the average of 2.88 million shares. The company holds a market capitalization of approximately $50.80 billion and operates within the healthcare equipment sector, maintaining a strong position with no sell ratings among analysts.
๐ EPS beat consensus by $0.04 at $0.78.
๐ฐ Revenue grew 13.6% YoY to $1.74 billion.
๐ฎ Full-year 2026 EPS expected between $2.95-$3.05.
Edwards Lifesciences stock opened higher on September 17, 2026, following a significant gain of approximately 4.1% during the trading session that concluded on September 16, 2026. The shares traded around USD 89 on the NYSE, outperforming the broader S&P 500 index which declined by roughly 0.4% on the same day. This relative strength positioned the stock in the upper half of its 52-week trading range, which spanned between approximately USD 72 and USD 96 at the time.
The company's share price climbed to about USD 89.28, representing a notable increase compared to the prior close. Market data from various sources highlighted Edwards Lifesciences as a top gainer, with some reports noting active trading interest and a rebound in sentiment after early selling pressure. The stock's performance was distinct from the wider market decline, indicating specific investor confidence or positive catalysts unrelated to general market downturns.
Edwards Lifesciences is scheduled to present at the Deutsche Bank 2026 Healthcare Summit on September 16, 2026, providing an opportunity for management to discuss growth priorities and industry trends. This upcoming event is expected to influence investor sentiment as trading unfolds ahead of and after the US opening bell. The company's participation underscores its active engagement with the investment community regarding future strategic directions.
๐ EW stock gained 4.1% to close near USD 89 on September 16, 2026.
๐ Shares outperformed the S&P 500 which declined 0.4% that day.
๐ Stock closed in the upper half of its USD 72-USD 96 range.
๐ฌ Management will present at Deutsche Bank Healthcare Summit on Sept 16.
๐ Sentiment rebounded after early selling pressure eased during trading.
๐ Edwards Lifesciences stock gained approximately 4.1% on September 16, 2026, closing around USD 89 on the NYSE.
๐ The shares outperformed the S&P 500, which declined by about 0.4% on the same day.
๐ The stock closed near the upper half of its 52-week trading range between USD 72 and USD 96.
๐ฌ Management is set to present at the Deutsche Bank 2026 Healthcare Summit on September 16, 2026.
๐ Trading activity showed a rebound in sentiment following early selling pressure.
๐ฐ Multiple financial outlets listed Edwards Lifesciences among notable US risers for the session.
Bullish Signals
Stock rose 4.1% to USD 89, outperforming S&P 500.
Closed near upper half of 52-week trading range.
Active trading interest and sentiment rebound observed.
Bullish Signals
Edwards Lifesciences stock rose approximately 4.1% to trade around USD 89, significantly outperforming the broader S&P 500 which fell by 0.4%.
The company closed near the upper half of its 52-week trading range, indicating strong relative performance against historical volatility.
Active trading interest and a rebound in sentiment were observed as short-term investors stepped in after early selling pressure.
As of September 15, 2026, Edwards Lifesciences Corporation (EW) trades at $85.52, which aligns with CleaRank Financial AI's fair value estimate but sits below the Wall Street consensus target of $101.50 set by 29 analysts. The stock is currently in oversold territory with an RSI of 28 and is trading beneath its 50-day average of $89.05, indicating bearish short-term technical momentum.
Fundamentally, the company has demonstrated a track record of beating analyst EPS estimates, most recently by 5.41% in the quarter ending June 2026. This consistent outperformance provides a foundation for potential future stock appreciation, while projections indicate the company is expected to achieve 11.00% revenue growth for the current year, reflecting continued market demand for its medical devices.
However, insider activity presents a cautionary signal, with insiders having sold approximately $34 million in stock and no reported purchases, potentially limiting near-term upside momentum. While CleaRank's Monte Carlo simulations project various long-term outcomes ranging from a bear case of roughly $5,496 to a bull case near $80,219 by 2036, these are statistical projections based on historical volatility and drift rather than guarantees of future performance.
๐ EW trades at $85.52, below the $101.50 Wall Street consensus target.
๐ RSI of 28 indicates oversold conditions as price sits under $89.05 average.
๐ EPS beat estimates by 5.41% for the quarter ending June 2026.
๐ Revenue projected to grow 11.00% this year supporting medical device narrative.
โ ๏ธ Insiders sold $34 million with no purchases signaling caution.
๐ EW trades at $85.52 as of September 15, 2026, which is in line with CleaRank's fair value but below the Wall Street consensus target of $101.50.
๐ The stock has an RSI of 28, placing it in oversold territory, and is trading below its 50-day average of $89.05.
๐ Edwards Lifesciences recently beat analyst EPS estimates by 5.41% in the quarter to June 2026.
๐ Revenue growth is projected at 11.00% for the current year, supporting the company's growth narrative in medical devices.
โ ๏ธ Insiders have sold approximately $34 million in stock with no reported purchases, signaling caution.
๐ Technical indicators show bearish short-term momentum as the price remains below its 50-day SMA and 20-day EMA.
๐ฎ CleaRank's 10-year Monte Carlo simulation projects a base case value of approximately $20,998 for a $10,000 investment by 2036.
Bullish Signals
Beat EPS estimates by 5.41% in Q2 2026.
Projected revenue growth of 11.00% for current year.
Risk Factors
Insiders sold $34M with no purchases.
Stock trades below 50-day SMA and 20-day EMA.
Bullish Signals
Edwards Lifesciences has a track record of beating analyst EPS estimates, most recently by 5.41% in the quarter to June 2026.
The company is projected to achieve 11.00% revenue growth for the current year, indicating continued market demand for its medical devices.
Risk Factors
Insiders have sold approximately $34 million in stock with no reported purchases, signaling a degree of caution and potentially limiting near-term upside momentum.
The stock is currently trading below its 50-day SMA and 20-day EMA, indicating bearish short-term technical momentum and potential for further price declines.
Edwards Lifesciences stock slipped approximately 2.8% to trade around $84.31 on September 11, 2026, following a Medicare coverage update for transcatheter aortic valve replacement (TAVR) procedures. Despite the immediate price dip, analysts from major firms like BTIG and Citi reaffirmed their Buy ratings with price targets of $110, signaling significant upside potential relative to current trading levels.
The company reaffirmed its full-year 2026 guidance, projecting sales growth between 10% and 11% and earnings per share (EPS) ranging from $2.95 to $3.05. This positive outlook follows a recent quarterly report where Edwards Lifesciences beat market expectations, reporting EPS of $0.78 against a consensus of $0.74 and revenue of $1.74 billion versus an expected $1.70 billion.
Analyst sentiment remains broadly positive, with 17 analysts rating the stock as Buy compared to six Hold ratings, resulting in a consensus Moderate Buy rating and an average price target near $101. However, some investors view the current valuation as a counterweight to growth, noting a premium P/E ratio of 51.54 that may limit multiple expansion even if sales continue to grow robustly.
The updated Medicare policy removes prior evidence development requirements for symptomatic severe aortic valve stenosis and extends coverage to certain asymptomatic cases, broadening access to the therapy. While this reduces regulatory uncertainty, investors are still calibrating the long-term impact on adoption rates and procedural volumes, with some viewing the stock's decline as a 'sell-the-news' reaction rather than a reflection of negative fundamentals.
๐ Shares dropped 2.8% to $84.31 amid new Medicare TAVR coverage rules.
โ Reaffirmed full-year 2026 guidance with 10-11% sales growth and $2.95-$3.05 EPS.
๐ Quarterly results beat expectations with $0.78 EPS and $1.74 billion revenue.
๐ BTIG and Citi maintain Buy ratings with $110 price targets implying 26-30% upside.
โ๏ธ Trades at premium P/E of 51.54 while trading 9% below GuruFocus value estimate.
๐ Edwards Lifesciences shares dropped 2.8% to $84.31 intraday on September 11, 2026, after opening at $87.51 as investors digested the new Medicare TAVR coverage rules.
โ The company reaffirmed full-year 2026 guidance with projected sales growth of 10-11% and EPS between $2.95 and $3.05.
๐ Recent quarterly results beat expectations, with EPS of $0.78 vs. consensus of $0.74 and revenue of $1.74 billion vs. $1.70 billion.
๐ Analysts at BTIG and Citi maintain Buy ratings with price targets set at $110, implying roughly 26-30% upside from current levels.
๐ The stock trades at a premium valuation with a P/E ratio of 51.54 and a market capitalization of approximately $50 billion.
๐ฅ CMS updated national coverage determination for TAVR, removing prior evidence requirements for symptomatic severe cases and extending access to certain asymptomatic patients.
๐ The stock has underperformed the S&P 500 year-to-date, posting a 1.06% return compared to the index's 12.0% gain.
โ๏ธ Canaccord reiterated a Hold rating citing a premium valuation that tempers optimism despite favorable regulatory outcomes.
๐ Quiver Quantitative attributes the share price decline to a muted 'sell-the-news' response rather than negative company-specific data.
๐ฎ GuruFocus calculates the stock trades about 9% below its GF Value estimate of $95.33, suggesting moderate undervaluation.
Bullish Signals
Full-year 2026 guidance reaffirmed with 10-11% sales growth.
Quarterly EPS beat consensus at $0.78 vs $0.74.
Revenue hit $1.74B, up 13.6% year over year.
Analysts maintain Buy ratings with ~$101 average target.
Risk Factors
Shares slipped 2.8% intraday to $84.31 on Medicare TAVR update.
Stock lagged S&P 500's 12.0% gain with only 1.06% YTD return.
Premium P/E of 51.54 may limit multiple expansion per Canaccord.
Investors calibrate long-term Medicare impact on hospital reimbursement levels.
Edwards Lifesciences (EW) shares edged higher on September 9, 2026, closing at USD 86.18 after the company raised its full-year 2026 revenue guidance. This positive move follows a robust second quarter where sales surged 13.6% year over year, driven by sustained demand for its heart valve and critical care products in key markets.
Management's decision to lift the 2026 revenue outlook signals increased confidence in the company's ability to expand its top-line results through the remainder of the fiscal year. The guidance upgrade provides investors with a clearer view of expected underlying demand and procedure volumes, reinforcing the current momentum observed in Q2 performance.
Despite the recent positive catalyst, EW stock has underperformed the broader market over the trailing twelve months, returning 7.99% compared to the S&P 500's 17.25% gain. Over a three-year period, the stock returned 16.35% versus 71.32% for the index, suggesting that while the company creates shareholder value, its shares have recently lagged the benchmark and may require time to catch up if execution meets the new higher guidance targets.
๐ Edwards raised 2026 revenue growth outlook after strong Q2 performance.
๐ฐ Q2 sales rose 13.6% year over year on product demand.
๐ Stock closed at USD 86.18, below recent highs near USD 89.
๐ One-year return was 7.99%, trailing S&P 500's 11.55% gain.
โณ Three-year return of 16.35% trailed S&P 500's 71.32% gain.
๐ Edwards Lifesciences raised its 2026 revenue growth outlook following a strong second quarter performance.
๐ฐ Q2 2026 sales increased by 13.6% year over year, highlighting continued demand for heart valve and critical care products.
๐ The stock closed at USD 86.18 on September 9, 2026, trading modestly below recent highs near USD 89.
๐ Year-to-date total return was 1.09%, while the one-year trailing return stood at 7.99%.
๐ The S&P 500 benchmark outperformed EW significantly over the past year with an 11.55% gain versus 7.99% for the company.
โณ Over a three-year span, Edwards Lifesciences returned 16.35%, trailing the S&P 500's 71.32% gain.
Bullish Signals
Raised 2026 revenue guidance after Q2 sales rose 13.6% YoY.
Management confident in expanding top-line through 2026 on strong demand.
Risk Factors
Stock underperformed S&P 500 with 7.99% vs 17.25% one-year return.
Lagged S&P 500 (16.35% vs 71.32%) over three years.
Bullish Signals
Edwards Lifesciences raised its 2026 revenue guidance following a robust Q2 2026 sales increase of 13.6% year over year.
Management demonstrated confidence in expanding top-line results through the remainder of 2026 based on solid underlying demand for heart valve and critical care products.
Risk Factors
The stock has significantly underperformed the S&P 500 benchmark, delivering a 7.99% one-year return compared to the index's 17.25% gain.
Over a three-year period, EW returned only 16.35% versus 71.32% for the S&P 500, indicating a prolonged lag that requires careful valuation assessment.
Edwards Lifesciences (NYSE: EW) is a specialized medical technology company dedicated exclusively to solving heart valve disease, having spent six decades becoming irreplaceable in the structural heart market. Every aspect of its business, from research programs to manufacturing, focuses on the four heart valves that regulate blood flow. The company's investment thesis relies on three key realities: the rapidly aging global population driving demand for valve replacements, a massive and widening treatment gap for patients with severe valve disease, and Edwards' unique combination of intellectual property, clinical evidence, and physician relationships accumulated over 65 years.
The article details Edwards' strategic transition from its dominant TAVR (transcatheter aortic valve replacement) franchise to a new multi-billion dollar opportunity in Transcatheter Mitral and Tricuspid Therapies (TMTT). While TAVR is maturing, the company is positioning itself to address the largest unmet need in structural cardiology: tricuspid regurgitation, which affects millions but has a treatment rate of less than 3%. Edwards holds a significant first-mover advantage in this space, having pioneered the technology and established rigorous clinical standards through landmark trials like PARTNER.
Historically founded by Dr. Miles Edwards and Dr. Albert Starr in 1958 to build an artificial heart valve, the company was spun out of Baxter International in 1999. A pivotal moment occurred in 2004 with the acquisition of Percutaneous Valve Technologies (PVT), which provided the foundational patents for TAVR. This acquisition established Edwards' habit of acquiring early-stage technology before regulatory pathways are clear, a strategy that has defined its growth. The company continues to navigate the transition from high-growth TAVR dominance to the emerging, high-prevalence markets of mitral and tricuspid interventions.
๐ฆ Aging population drives structural, time-locked compounding of the patient pool.
๐ 30โ50% of symptomatic aortic stenosis patients remain untreated globally.
๐ Transitioning from mature TAVR to multi-billion dollar Transcatheter Mitral/Tricuspid Therapies.
๐ฌ Holds unique IP and clinical evidence from landmark trials like PARTNER.
โณ TAVR valves must last 15 years to enable earlier asymptomatic treatment.
๐ฅ Edwards Lifesciences (EW) is a singular-focus medical technology company dedicated entirely to solving heart valve disease across four specific valves.
๐ฐ The investment thesis relies on the rapidly aging global population and a structural, time-locked compounding of the patient pool driven by biological calcification.
๐ A massive treatment gap exists for severe valve disease, with 30โ50% of symptomatic aortic stenosis patients untreated and over 90% of mitral/tricuspid cases receiving no intervention.
๐ Edwards is transitioning from its mature TAVR franchise to a new multi-billion dollar opportunity in Transcatheter Mitral and Tricuspid Therapies (TMTT).
๐ฌ The company holds unique intellectual property, clinical evidence from landmark trials like PARTNER, and deep physician relationships accumulated over 65 years.
๐ค In 2004, Edwards acquired Percutaneous Valve Technologies (PVT) for approximately $125 million to secure foundational TAVR patents and establish a culture of early-stage acquisition.
๐ฉบ Tricuspid regurgitation is identified as the largest single unmet need in structural cardiology, affecting an estimated 10 million people globally with less than 3% receiving intervention.
โณ Edwards faces a critical data challenge regarding the lifespan of TAVR valves, which currently needs to last at least 15 years to overcome hesitation for earlier asymptomatic treatment.
๐ The company has successfully navigated from its origins in 1958 to becoming an independent public entity in 1999 with a mandate to innovate beyond surgical tissue valves.
Bullish Signals
Edwards Lifesciences possesses a unique combination of intellectual property, clinical evidence, and manufacturing expertise accumulated over 65 years that no competitor has yet replicated.
The company is transitioning into Transcatheter Mitral and Tricuspid Therapies (TMTT), a new multi-billion dollar franchise emerging exactly as patient populations receive first meaningful treatment options.
Edwards holds the foundational patents for TAVR acquired via the 2004 Percutaneous Valve Technologies deal, establishing a dominant position in the maturing TAVR market.
The company has established an evidentiary standard through landmark randomized controlled trials like PARTNER that competitors must match to gain market share.
Edwards addresses a structural, time-locked compounding of the patient pool driven by biological calcification and aging demographics without needing to grow market share.
Risk Factors
The critical data regarding the lifespan of TAVR valves is currently holding back changes in treatment plans, as repeat surgery is highly challenging if the valve does not last at least 15 years.
Edwards is navigating a strategic transition where its dominant TAVR technology is maturing and no longer offers the hypergrowth driver it once possessed.
Edwards Lifesciences Corporation (NYSE: EW) reported strong quarterly financial results, posting earnings per share (EPS) of $0.78, which beat the analyst consensus of $0.74. Revenue increased by 13.6% year over year to reach $1.74 billion, exceeding expectations of $1.70 billion. The company maintains a robust balance sheet with a current ratio of 4.52 and a debt-to-equity ratio of 0.06, reflecting its strong financial position in the structural heart disease market.
The company has issued forward guidance for the third quarter of 2026, projecting EPS between $0.71 and $0.77, and full-year 2026 EPS between $2.95 and $3.05. Analyst sentiment remains favorable with a consensus rating of 'Moderate Buy' and an average price target of $100.27, significantly above the reported share price of approximately $90. Several major analysts have recently raised their price targets or upgraded ratings, citing continued growth potential.
Institutional ownership stands at 79.46%, though Azimuth Capital Investment Management LLC reduced its stake by 9.9% in the second quarter, selling 22,092 shares while retaining a position valued at roughly $18.2 million. Despite this reduction, other hedge funds have initiated new positions or increased holdings during various quarters, indicating continued institutional interest. Insider trading activity shows minor sales by executives under pre-arranged plans, with corporate insiders owning 0.31% of the stock.
๐ Edwards beat EPS estimates at $0.78 with revenue up 13.6% to $1.74B.
๐ฎ Company guides Q3 2026 EPS of $0.71โ$0.77 and full-year 2026 of $2.95โ$3.05.
๐ Azimuth Capital reduced stake by 9.9%, selling 22,092 shares in Q2.
๐ฏ Analysts maintain Moderate Buy consensus with average price target of $100.27.
๐ผ UBS initiated Buy rating at $110; JPMorgan raised target to $105.
๐ Edwards Lifesciences reported quarterly EPS of $0.78, beating analyst estimates of $0.74.
๐ฐ Revenue grew 13.6% year over year to $1.74 billion, surpassing the $1.70 billion consensus.
๐ฎ The company issued Q3 2026 EPS guidance of $0.71โ$0.77 and full-year 2026 guidance of $2.95โ$3.05.
๐ Azimuth Capital reduced its stake by 9.9% in the second quarter, selling 22,092 shares.
๐ฆ Institutional investors collectively own 79.46% of Edwards Lifesciences Corporation.
๐ The stock trades at a PE ratio of 51.72 with a market capitalization of $51.82 billion.
๐ฏ Analysts maintain a 'Moderate Buy' consensus with an average price target of $100.27 versus the current price of ~$90.
๐ UBS Group initiated coverage with a 'Buy' rating and a $110.00 price target.
๐ผ JPMorgan Chase raised its price target from $100.00 to $105.00 with an 'overweight' rating.
๐ VP Daniel J. Lippis sold 619 shares under a Rule 10b5-1 trading plan on August 11th.
๐ SVP Andrew M. Dahl sold 544 shares on August 31st, reducing his ownership by 3.53%.
๐ฅ The company focuses on prosthetic heart valves and transcatheter aortic valve replacement (TAVR) technologies.
Bullish Signals
EPS beat estimates at $0.78 vs $0.74.
Revenue grew 13.6% YoY to $1.74 billion.
Raised Q3 and full-year 2026 EPS guidance.
Institutional ownership stands high at 79.46%.
Risk Factors
Azimuth Capital sold 22,092 shares, dropping holdings by 9.9%.
Insiders Lippis and Dahl reduced positions via pre-arranged plans.
Bullish Signals
Edwards Lifesciences beat quarterly EPS estimates of $0.74 with a reported result of $0.78.
Revenue increased 13.6% year over year to $1.74 billion, exceeding analyst expectations of $1.70 billion.
The company issued optimistic forward guidance for Q3 2026 EPS ($0.71โ$0.77) and full-year 2026 EPS ($2.95โ$3.05).
Institutional ownership remains high at 79.46%, indicating strong confidence from major investors.
Analyst consensus is 'Moderate Buy' with an average price target of $100.27, implying significant upside from the current ~$90 price.
UBS Group initiated coverage with a 'Buy' rating and a high $110.00 price target.
JPMorgan Chase upgraded its stance to 'overweight' and raised its price target to $105.00.
Royal Bank of Canada increased its price objective to $110.00 with an 'outperform' rating.
Leerink Partners upgraded the stock from 'market perform' to 'outperform' and raised the price target to $101.00.
Risk Factors
Azimuth Capital Investment Management LLC decreased its holdings by 9.9% in the second quarter, selling 22,092 shares.
Insider sales occurred recently, with VP Daniel J. Lippis and SVP Andrew M. Dahl reducing their positions under pre-arranged trading plans.
Edwards Lifesciences Corporation (NYSE: EW) reported stronger-than-expected quarterly results, posting $0.78 in earnings per share and $1.74 billion in revenue, representing a 13.6% year-over-year increase. The company's stock opened at $90.00, trading near the middle of its 12-month range, with analysts maintaining a 'Moderate Buy' consensus and an average price target of $100.27.
Institutional ownership dynamics shifted in the second quarter as B. Metzler seel. Sohn & Co. AG reduced its stake by 25.5%, selling 14,264 shares while retaining a position valued at approximately $3.78 million. Conversely, several other institutional investors increased their holdings during the fourth quarter, including Rehmann Capital Advisory Group, Quadrant Capital Group LLC, and Covestor Ltd, signaling continued institutional interest despite the reduction by Metzler.
Analyst sentiment remains robust with 17 Buy ratings against six Holds from major firms like UBS Group, Royal Bank of Canada, and TD Cowen. The company maintains a strong balance sheet with a current ratio of 4.52 and minimal debt, while insiders have sold a total of 5,045 shares in the last ninety days under pre-arranged trading plans.
๐ Edwards beat EPS and revenue estimates at $0.78 and $1.74B.
๐ B. Metzler sold 25.5% of stake, reducing position by 14,264 shares.
๐ Institutional investors Rehmann Capital and Covestor increased EW stakes in Q4.
๐ฐ Strong balance sheet with current ratio of 4.52 and debt-to-equity of 0.06.
๐ฏ Analysts maintain Moderate Buy consensus with $100.27 average price target.
๐ Edwards Lifesciences reported quarterly EPS of $0.78 and revenue of $1.74 billion, beating analyst estimates.
๐ B. Metzler seel. Sohn & Co. AG lowered its position by 25.5% in Q2, selling 14,264 shares.
๐ Multiple institutional investors including Rehmann Capital and Covestor Ltd increased their EW stakes in Q4.
๐ฐ The company maintains a strong balance sheet with a current ratio of 4.52 and a debt-to-equity ratio of 0.06.
๐ฏ Analysts maintain a 'Moderate Buy' consensus with an average price target of $100.27.
๐ Revenue grew 13.6% year over year, demonstrating solid top-line growth for the medical device firm.
Bullish Signals
EPS hit $0.78, revenue reached $1.74B, both beating estimates.
Risk Factors
B. Metzler reduced stake by 25.5%, selling 14,264 shares.
Insiders sold 5,045 shares worth $457,749 in 90 days.
Bullish Signals
Edwards Lifesciences reported quarterly EPS of $0.78 and revenue of $1.74 billion, both exceeding analyst estimates.
The company achieved a 13.6% year-over-year revenue increase, demonstrating strong business growth.
Institutional investors such as Rehmann Capital Advisory Group and Covestor Ltd increased their holdings in Q4.
Analyst consensus remains 'Moderate Buy' with an average price target of $100.27, indicating confidence in future performance.
Risk Factors
B. Metzler seel. Sohn & Co. AG reduced its stake by 25.5% in the second quarter, selling 14,264 shares.
Corporate insiders sold a total of 5,045 shares valued at $457,749 in the last ninety days.
Edwards Lifesciences Corporation (NYSE: EW) reported strong quarterly financial results, exceeding analyst expectations with earnings per share of $0.78 against a consensus of $0.74 and revenue of $1.74 billion, representing a 13.6% year-over-year increase. The company demonstrated robust profitability with a net margin of 15.43% and a return on equity of 15.68%, while maintaining a healthy balance sheet characterized by a low debt-to-equity ratio of 0.06 and strong liquidity metrics.
Institutional interest in the medical technology company remains high, highlighted by Nykredit A/S acquiring a new stake valued at approximately $20.64 million during the second quarter. Other institutional investors, including Robbins Farley and Natural Investments LLC, also increased their holdings, reflecting continued confidence in Edwards' market position within structural heart disease and critical care monitoring sectors.
Analyst sentiment is predominantly positive, with a consensus rating of 'Moderate Buy' and an average price target of $100.27, which sits above the recent trading range near $89.89. Major financial institutions such as Citigroup, BTIG Research, and Mizuho have recently upgraded their price targets or maintained buy ratings, citing the company's growth trajectory and technological leadership in transcatheter aortic valve replacement procedures.
๐ Edwards beat earnings with $0.78 EPS vs $0.74 consensus.
๐ฐ Revenue surged 13.6% to $1.74 billion year-over-year.
๐ฆ Nykredit A/S invested $20.64 million buying 228,193 shares.
๐ก๏ธ Strong balance sheet with debt-to-equity ratio of just 0.06.
๐ Major banks raised price targets to $110.00 per share.
๐ Edwards Lifesciences beat quarterly earnings expectations with $0.78 EPS versus the $0.74 consensus estimate.
๐ฐ Revenue surged to $1.74 billion, marking a 13.6% increase compared to the same period last year.
๐ฆ Nykredit A/S invested $20.64 million in the company by acquiring 228,193 shares in the second quarter.
๐ Institutional ownership stands at 79.46%, with several funds like Robbins Farley increasing their stakes.
๐ฏ Analysts maintain a 'Moderate Buy' consensus with an average price target of $100.27 per share.
๐ก๏ธ The company boasts a strong balance sheet with a debt-to-equity ratio of just 0.06 and a current ratio of 4.52.
๐ Insider selling occurred recently as VP Annette Brรผls and SVP Andrew M. Dahl sold shares totaling $457,749 over 90 days.
๐ Major banks including Citigroup and BTIG Research raised their price targets to $110.00 following recent reports.
๐ Stock traded near $89.89 recently, having ranged between $72.30 and $96.29 over the past year.
๐ The firm provides prosthetic heart valves and delivery systems for both surgical and minimally invasive procedures.
Bullish Signals
EPS beat at $0.78 vs $0.74 consensus.
Revenue up 13.6% YoY to $1.74 billion.
Nykredit invested $20.64M, boosting confidence.
Debt-to-equity ratio is a strong 0.06.
Analysts upgraded targets to $110.00.
Risk Factors
Insiders sold 5,045 shares worth $457,749 in 90 days.
Stock traded near $89.89 below $100.27 analyst target.
Bullish Signals
Edwards Lifesciences exceeded quarterly earnings expectations, reporting $0.78 in EPS compared to the $0.74 consensus estimate.
Revenue grew significantly to $1.74 billion, representing a 13.6% year-over-year increase driven by strong demand for heart valve technologies.
Nykredit A/S made a substantial new investment of $20.64 million in the second quarter, signaling strong institutional confidence.
The company maintains a robust balance sheet with a debt-to-equity ratio of 0.06 and a current ratio of 4.52, indicating strong liquidity.
Major analysts including Citigroup and BTIG Research upgraded price targets to $110.00, reflecting optimism about future growth prospects.
The company achieved a net margin of 15.43% and a return on equity of 15.68%, demonstrating efficient operations and profitability.
Risk Factors
Company insiders sold 5,045 shares worth approximately $457,749 over the past 90 days, including sales by VP Annette Brรผls and SVP Andrew M. Dahl.
The stock recently traded near $89.89, which is below the average analyst price target of $100.27, suggesting potential upside but also room for volatility.
Edwards Lifesciences Corp (EW) is a medical technology company specializing in structural heart disease and critical care, having separated from Baxter International in 2000. The firm is renowned for its heart valve replacement and repair technologies, including surgical tissue valves and transcatheter systems that have revolutionized treatment for patients with aortic stenosis who are at high risk for open-heart surgery.
Beyond aortic interventions, Edwards is developing therapies for mitral and tricuspid valves, positioning itself in complex valve disorders as a key long-term growth market. Operating within a highly regulated environment, the company relies on clinical evidence, physician training, and approvals from bodies like the US FDA to maintain its competitive position while selling to hospitals globally with significant revenue generated outside the United States.
For investors, EW offers exposure to specialized cardiovascular devices driven by demographic trends and minimally invasive procedure adoption. Analyst sentiment is strongly positive, with 72% of analysts rating the stock a Buy and recent upgrades outnumbering downgrades over the last month. Technical indicators also support a bullish outlook, with the stock trading above key moving averages.
Despite the strong analyst and technical sentiment, insider selling remains a notable negative factor, as executives were net sellers of approximately $4.9 million in stock over the last 90 days with no meaningful purchases recorded. The article notes that no recent specific news is currently linked to this listing, suggesting the current market view relies on established fundamentals rather than immediate catalysts.
๐ฅ Edwards Lifesciences focuses on structural heart disease and critical care innovation since 2000.
๐ Best known for transcatheter aortic valve replacement systems treating high-risk patients.
๐ฌ Expanding portfolio into mitral and tricuspid therapies for future growth.
๐ Substantial revenue generated outside the United States via global hospital sales.
๐ Analyst sentiment is strongly positive with 72% rating the stock a Buy.
๐ฅ Edwards Lifesciences focuses on structural heart disease and critical care innovation following its 2000 separation from Baxter International.
๐ The company is best known for transcatheter aortic valve replacement systems that treat high-risk patients with aortic stenosis.
๐ฌ Edwards is expanding its portfolio into mitral and tricuspid therapies to address complex valve disorders as future growth markets.
๐ A substantial share of the company's revenue is generated outside the United States through global hospital sales.
๐ Analyst sentiment is strongly positive with 72% of analysts rating the stock a Buy.
๐ Recent analyst activity shows more upgrades than downgrades over the last 30 days.
๐ Technical signals are bullish, with the price trading above both 50-day and 200-day moving averages.
๐ฐ Insiders were net sellers of approximately $4.9 million in stock over the last 90 days.
๐ No meaningful insider purchases were recorded during the same period.
Bullish Signals
72% of analysts rate Edwards Lifesciences as Buy.
More upgrades than downgrades in last 30 days.
Stock trades above 50-day and 200-day moving averages.
Bullish MACD momentum and RSI trend.
Risk Factors
Insiders sold $4.9M in stock over last 90 days.
No meaningful insider purchases recorded recently.
Bullish Signals
Analyst sentiment remains strongly positive with 72% of analysts rating Edwards Lifesciences a Buy.
Recent analyst activity shows more upgrades than downgrades over the last 30 days, indicating growing confidence.
Technical indicators are bullish, with the stock price trading above both the 50-day and 200-day moving averages.
MACD momentum is supportive while the Relative Strength Index (RSI) indicates a bullish trend.
Risk Factors
Insiders were net sellers of approximately $4.9 million in Edwards Lifesciences stock over the last 90 days.
No meaningful insider purchases were recorded, suggesting a lack of confidence from company executives at current levels.
Edwards Lifesciences Corporation (NYSE:EW) shares opened significantly higher on Friday following a quarterly earnings report that exceeded analyst expectations. The stock gapped up from a previous close of $83.82 to an opening price of $88.00, trading at $86.84 with a volume of 1.41 million shares. This positive market reaction was driven by the company's ability to beat consensus estimates on both earnings per share and revenue.
The medical technology firm reported quarterly EPS of $0.78, surpassing the consensus estimate of $0.74, while generating revenue of $1.74 billion against an expected $1.70 billion. Key financial metrics included a return on equity of 15.85% and a net margin of 15.43%. Year-over-year revenue growth was robust at 13.6%, with EPS rising from $0.67 in the prior year period, indicating strong operational performance.
Looking ahead, Edwards Lifesciences provided guidance for Q3 2026 EPS between $0.710 and $0.770, and full-year FY 2026 EPS between $2.950 and $3.050. The company focuses on structural heart disease therapies, specifically prosthetic heart valves for surgical and transcatheter procedures like TAVR. Despite insider selling by senior executives under pre-arranged plans, major institutional investors including Norges Bank, UBS, Viking Global, Marshall Wace, and Bank of America have recently increased their stakes in the company.
๐ EPS beat consensus at $0.78, driving shares to $88.00.
๐ฐ Revenue hit $1.74B, up 13.6% year-over-year.
๐ฎ FY2026 EPS guidance raised to $2.95-$3.05 range.
๐ฆ Major institutions increased holdings in the stock.
๐ Stock trades at PE of 47.51 with $47.6B market cap.
๐ Edwards Lifesciences shares gapped up to $88.00 following a quarterly earnings beat where EPS reached $0.78 versus the $0.74 consensus estimate.
๐ฐ Revenue for the quarter totaled $1.74 billion, exceeding expectations of $1.70 billion and growing 13.6% compared to the same period last year.
๐ The company reported a return on equity of 15.85% and a net margin of 15.43%, demonstrating strong profitability metrics.
๐ฎ Management raised full-year FY 2026 EPS guidance to a range of $2.950-$3.050, signaling confidence in future performance.
๐ฆ Major institutional investors including Norges Bank, UBS, Viking Global, Marshall Wace, and Bank of America have recently increased their holdings in the stock.
๐ Senior executives Andrew Dahl and Daniel Lippis sold shares under pre-arranged Rule 10b5-1 trading plans, reducing their direct ownership by approximately 3.5% and 1.5% respectively.
๐ผ The company maintains a strong balance sheet with a debt-to-equity ratio of 0.06 and a current ratio of 4.42.
๐ฅ Edwards Lifesciences specializes in structural heart disease therapies, including the SAPIEN family of transcatheter heart valves used as alternatives to open-heart surgery.
๐ The stock trades at a PE ratio of 47.51 with a market capitalization of $47.60 billion and a beta of 0.86.
Bullish Signals
Beat EPS estimates by $0.04 at $0.78 per share.
Revenue of $1.74 billion exceeded analyst expectations.
Year-over-year revenue growth reached 13.6%.
Raised guidance for Q3 and FY 2026 EPS.
Institutional investors increased stakes significantly, including UBS.
Debt-to-equity ratio remains extremely low at 0.06.
Strong liquidity with current ratio of 4.42.
Risk Factors
Senior VP Andrew M. Dahl sold 568 shares ($48,893.44).
VP Daniel J. Lippis sold 619 shares ($56,762.30).
Bullish Signals
The company beat quarterly EPS estimates by $0.04, reporting $0.78 per share compared to the consensus of $0.74.
Revenue of $1.74 billion exceeded analyst expectations of $1.70 billion, showing strong top-line execution.
Year-over-year revenue growth of 13.6% demonstrates sustained demand for the company's heart valve technologies.
Management provided raised guidance for Q3 2026 EPS ($0.710-$0.770) and FY 2026 EPS ($2.950-$3.050).
Significant capital inflows from major institutional investors, including a 278.3% stake increase by UBS and new positions by Viking Global and Bank of America.
The company maintains an extremely low debt-to-equity ratio of 0.06, indicating minimal financial leverage and strong solvency.
Strong liquidity position evidenced by a current ratio of 4.42 and quick ratio of 3.63.
Risk Factors
Senior Vice President Andrew M. Dahl sold 568 shares worth $48,893.44, representing a 3.57% decrease in his direct ownership.
Vice President Daniel J. Lippis sold 619 shares worth $56,762.30, reducing his direct ownership by 1.52%.
Institutional investors have significantly increased their stakes in Edwards Lifesciences Corporation (NYSE:EW) during the first quarter of 2026. AIA Group Ltd raised its position by 7.9%, adding over 10,000 shares worth nearly $11 million. Major additions also came from Norges Bank, UBS Asset Management, Viking Global Investors, Marshall Wace LLP, and Allspring Global Investments, with combined holdings representing a substantial portion of the company's float.
Financial performance remains robust following the Q1 2026 earnings report released on April 23rd. Edwards Lifesciences reported EPS of $0.78, beating analyst estimates of $0.73, and revenue of $1.65 billion, which exceeded expectations of $1.60 billion. The company achieved a net margin of 17.39% and demonstrated strong growth with quarterly revenue up 16.7% year-over-year compared to the previous period.
Analyst sentiment is overwhelmingly positive, with multiple firms raising price targets and maintaining buy ratings. Mizuho increased its target to $105, BTIG raised it to $110, and Barclays set a target of $110. The consensus average price target stands at $98.95, while the company has provided FY 2026 guidance between $2.95 and $3.05 per share. Despite some insider selling by Vice Presidents Donald Bobo Jr. and Daniel Lippis, institutional ownership remains high at 79.46%.
Edwards Lifesciences continues to focus on structural heart disease treatments, specifically transcatheter aortic valve replacement (TAVR) technologies like the SAPIEN family. The company's portfolio includes both surgical and minimally invasive prosthetic heart valves designed for cardiac surgeons and interventional cardiologists. This strategic focus supports its position as a leader in medical technology for critical care monitoring and valvular conditions.
๐ AIA Group increased holdings by 7.9% to own over $10.9 million.
๐ฆ Norges Bank established a new position valued at approximately $803.7 million.
๐ฐ Q1 2026 earnings beat with EPS of $0.78 and revenue of $1.65 billion.
๐ฏ Analysts raised price targets, with BTIG increasing its to $110.
๐ Institutional investors aggressively accumulated shares, with AIA Group increasing holdings by 7.9% to own over $10.9 million worth of stock.
๐ฆ Norges Bank established a new position valued at approximately $803.7 million, while UBS Asset Management grew its stake by 278.3%.
๐ฐ Q1 2026 earnings beat expectations with EPS of $0.78 versus the consensus of $0.73 and revenue of $1.65 billion against a forecast of $1.60 billion.
๐ Revenue grew 16.7% year-over-year, driven by strong performance in structural heart disease products and transcatheter valve technologies.
๐ฏ Analysts are raising price targets, with Mizuho setting a new target of $105 and BTIG increasing its to $110.
๐ The company provided FY 2026 EPS guidance ranging from $2.95 to $3.05, indicating continued growth expectations.
๐ Insider selling occurred as VP Donald Bobo Jr. sold shares worth over $2 million and VP Daniel Lippis sold a smaller tranche under a pre-arranged plan.
๐ Institutional ownership remains high at 79.46%, signaling strong confidence from major asset managers and hedge funds.
๐ฌ The company maintains a diverse portfolio including the SAPIEN family of valves for both surgical and minimally invasive procedures.
Bullish Signals
AIA Group stake rose 7.9%.
Norges Bank added over $800M.
Q1 2026 EPS beat $0.05.
Revenue grew 16.7% year-over-year.
Net margin reached 17.39%.
Risk Factors
VPs sold over $2M in shares this quarter.
Insider ownership is low at just 0.31%.
Bullish Signals
Significant institutional buying activity, with AIA Group adding 7.9% to its stake and Norges Bank initiating a massive new position worth over $800 million.
Strong Q1 2026 financial results showing an EPS beat of $0.05 and revenue growth of 16.7% year-over-year.
Multiple major analysts raising price targets, including Mizuho to $105, BTIG to $110, and Barclays to $110.
Robust profitability metrics with a net margin of 17.39% and a return on equity of 15.19%.
Positive analyst consensus with an average price target of $98.95 and a 'Moderate Buy' rating from MarketBeat.
Clear forward guidance for FY 2026 EPS between $2.95 and $3.05, suggesting sustained earnings growth.
Risk Factors
Insider selling activity by Vice Presidents Donald Bobo Jr. and Daniel Lippis, totaling over $2 million in shares sold during the quarter.
Low insider ownership at only 0.31% of the company's stock, indicating limited direct skin-in-the-game from top management.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)